Initiator Pharma develops monoamine reuptake inhibitors targeting monoamine transporters to enhance neurotransmitter levels in patients with erectile dysfunction and trigeminal neuralgia. The company addresses the significant unmet medical needs of the 297 million men affected by erectile dysfunction worldwide, particularly those who do not respond to existing drug therapies.
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Erectile dysfunction (ED) affects a significant portion of the male population, with a substantial number of men not responding to currently available treatments. Trigeminal neuralgia also presents a challenging condition with limited effective therapeutic options.
Solution
Initiator Pharma develops monoamine reuptake inhibitors designed to modulate monoamine transporter activity, thereby increasing neurotransmitter levels to address unmet medical needs in erectile dysfunction and trigeminal neuralgia. Their approach focuses on a unique class of proteins located peri-synaptically, which transport monoamine transmitter overflow from the synaptic cleft back to the pre-synaptic neuron. By targeting these monoamine transporters, Initiator Pharma aims to enhance neurotransmitter levels, potentially offering therapeutic benefits for patients who do not respond to existing drug therapies. The company has a portfolio of projects in clinical and preclinical development.
Target Audience
The primary target audience includes men affected by erectile dysfunction, particularly those who are non-responsive to existing drug therapies, as well as individuals suffering from trigeminal neuralgia.
Features
- Development of monoamine reuptake inhibitors targeting monoamine transporters.
- Focus on increasing neurotransmitter levels in the synaptic cleft.
- Pipeline includes projects in clinical and preclinical stages.
- Lead candidate, Pudafensin, has shown statistically significant and clinically relevant Phase IIb efficacy data.
- Targeting a unique class of peri-synaptic proteins.